Travere Therapeutics Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Travere Therapeutics (TVTX) Tops Q1 EPS by 3c
May 5, 2022 5:18 PM EDTTravere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.82), $0.03 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $48.5 million versus the consensus estimate of $51.92 million.
Cash, cash equivalents and marketable securities, as of March 31, 2022, totaled $603.4 million.
For earnings history and... More
